Discovery of PF-05212384/PKI-587: A phase 2 clinical PI3K/mTOR inhibitor

被引：0
|
作者：
Dehnhardt, Christoph M. [1 ]
Venkatesan, Aranapkam M. [1 ]
Delos Santos, Efren [1 ]
Kaloustian, Semiramis Ayral [1 ]
Broojimans, Natasja [1 ]
Hollander, Irwin [2 ]
Chen, Zecheng [1 ]
Lucas, Judy [1 ]
Mallon, Robert [2 ]
Verheijen, Jeroen [1 ]
Zask, Arie [1 ]
Khafizofa, Gulnaz [1 ]
Bursavich, Matt [2 ]
Richard, David [1 ]
Mansour, Tarek [1 ]
机构：
[1] Pfizer, Pearl River, NY 10965 USA
[2] Wyeth, Pearl River, NY 10965 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2014年 / 248卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
287-MEDI
引用
收藏
页数：1
相关论文
共 50 条
  • [1] First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
    Shapiro, Geoffrey I.
    Bell-McGuinn, Katherine M.
    Molina, Julian R.
    Bendell, Johanna
    Spicer, James
    Kwak, Eunice L.
    Pandya, Susan S.
    Millham, Robert
    Borzillo, Gary
    Pierce, Kristen J.
    Han, Lixin
    Houk, Brett E.
    Gallo, Jorge D.
    Alsina, Maria
    Brana, Irene
    Tabernero, Josep
    CLINICAL CANCER RESEARCH, 2015, 21 (08) : 1888 - 1895
  • [2] Process development of the PI3K/mTOR inhibitor PKI-587
    Dugger, Bob
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [3] Beyond temsirolimus: Discovery of PKI-587 a highly efficacious dual PI3K/mTOR inhibitor
    Venkatesan, Aranapakam M.
    Dehnhardt, Christoph M.
    Delos Santos, Efren
    Chen, Zecheng
    Dos Santos, Osvaldo
    Ayral-Kaloustian, Semiramis
    Mallon, Robert
    Hollander, Irwin
    Feldberg, Larry
    Lucas, Judy
    Yu, Ker
    Brooijmans, Natasja
    Bard, Joel
    Gibbons, James
    Abraham, Robert T.
    Mansour, Tarek S.
    CANCER RESEARCH, 2010, 70
  • [4] Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with other antitumor agents.
    Wainberg, Zev A.
    Shapiro, Geoffrey
    Curigliano, Giuseppe
    Leong, Stephen
    Kristeleit, Rebecca Sophie
    Maqueda, Maria Alsina
    Britten, Carolyn D.
    Milella, Michele
    Middleton, Mark R.
    Olszanski, Anthony J.
    Vaishampayan, Ulka N.
    Lopez-Martin, Jose A.
    Gelmon, Karen A.
    Brega, Nicoletta
    Pierce, Kristen J.
    Perea, Rachelle
    Houk, Brett Edward
    Pathan, Nuzhat
    Gollerkeri, Ashwin
    Razak, Albiruni R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor
    Mallon, Robert
    Feldberg, Larry R.
    Lucas, Judy
    Chaudhary, Inder
    Dehnhardt, Christoph
    Delos Santos, Efren
    Chen, Zecheng
    dos Santos, Osvaldo
    Ayral-Kaloustian, Semiramis
    Venkatesan, Aranapakam
    Hollander, Irwin
    CLINICAL CANCER RESEARCH, 2011, 17 (10) : 3193 - 3203
  • [6] Phase I study of the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with docetaxel, cisplatin, and dacomitinib
    Wainberg, Zev A.
    Shapiro, Geoffrey
    Curigliano, Giuseppe
    Kristeleit, Rebecca Sophie
    Leong, Stephen
    Alsina, Maria
    Milella, Michele
    Britten, Carolyn D.
    Gelmon, Karen A.
    Olszanski, Anthony J.
    Vaishampayan, Ulka N.
    Lopez-Martin, Jose A.
    Kern, Kenneth Alan
    Pierce, Kristen J.
    Perea, Rachelle
    Houk, Brett
    Pathan, Nuzhat
    Razak, Albiruni R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384
    Leiker, A.
    DeGraff, W.
    Choudhuri, R.
    Sowers, A. L.
    Thetford, A.
    Cook, J. A.
    Van Waes, C.
    Mitchell, J. B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S196 - S197
  • [8] Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384
    Leiker, Andrew J.
    DeGraff, William
    Choudhuri, Rajani
    Sowers, Anastasia L.
    Thetford, Angela
    Cook, John A.
    Van Waes, Carter
    Mitchell, James B.
    CLINICAL CANCER RESEARCH, 2015, 21 (12) : 2792 - 2801
  • [9] Pediatric relapsed acute lymphoblastic leukemia patients display enrichment of the PI3K/mTOR pathway and respond to the dual PI3K/mTOR inhibitor PKI-587
    Gazi, Mohiuddin
    Moharram, Sausan A.
    Marhall, Alissa
    Shah, Kinjal
    Kazi, Julhash U.
    CANCER RESEARCH, 2017, 77
  • [10] Phase 2 Trial of Single Agent Gedatolisib (PF-05212384), a Dual PI3K/mTOR Inhibitor, for Adverse Prognosis and Relapse/Refractory AML: Clinical and Transcriptomic Results
    Vargaftig, Jacques
    Farhat, Hassan
    Ades, Lionel
    Briaux, Adrien
    Benoist, Camille
    Turbiez, Isabelle
    Vey, Norbert
    Glaisner, Sylvie
    Callens, Celine
    BLOOD, 2018, 132
12345